Trading was light with 5 shares changing hands by the end of trading on Tuesday. Overall, volume was down 98.06% under the stocks normal daily volume.
Investors are feeling more bullish on Cyclacel Pharmaceuti of late if you consider the fall in short interest. The stock realized a fall in short interest of -19.80% as of the latest report on October 13, 2017. Short interest fell from 1,818 to 1,458 over that period. With short interest at 1,458 and short average daily volume at 888, the short-interest ratio is 2.0 and the short interest percentage is 4.35% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (CYCCP). As of quarter end Ubs Group Ag had disposed of 1,356 shares trimming its holdings by 69.0%. The value in dollars went from $12,000 to $4,000 decreasing 66.7% quarter to quarter. Tower Research Capital LLC (trc) downsized its ownership by selling 381 shares a decrease of 90.1%. Tower Research Capital LLC (trc) controls 42 shares with a value of $0. The value of the position overall is down by 100.0%.
In the market the company is trading unchanged since yesterday’s close of 6.00. The P/E ratio is N/A and the market value is 19.40M. In the latest earnings report the EPS was $-2.46 with 335 shares currently outstanding.
Cyclacel Pharmaceuticals, Inc., launched on January 5, 1996, operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. The Business’s family of anticancer drugs acts on the cell cycle..